WO2004048409A3 - Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids - Google Patents

Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids Download PDF

Info

Publication number
WO2004048409A3
WO2004048409A3 PCT/SI2003/000041 SI0300041W WO2004048409A3 WO 2004048409 A3 WO2004048409 A3 WO 2004048409A3 SI 0300041 W SI0300041 W SI 0300041W WO 2004048409 A3 WO2004048409 A3 WO 2004048409A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutants
deletion
amino acids
terminal amino
necrosis factor
Prior art date
Application number
PCT/SI2003/000041
Other languages
French (fr)
Other versions
WO2004048409A2 (en
Inventor
Viktor Menart
Vladka Gaberc-Porekar
Maja Kenig
Irena Fonda
Original Assignee
Lek Pharmaceuticals
Viktor Menart
Vladka Gaberc-Porekar
Maja Kenig
Irena Fonda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals, Viktor Menart, Vladka Gaberc-Porekar, Maja Kenig, Irena Fonda filed Critical Lek Pharmaceuticals
Priority to AU2003283947A priority Critical patent/AU2003283947A1/en
Publication of WO2004048409A2 publication Critical patent/WO2004048409A2/en
Publication of WO2004048409A3 publication Critical patent/WO2004048409A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to new protein analogues, especially TNF-alpha analogues in which the biological activity is modulated.
PCT/SI2003/000041 2002-11-22 2003-11-21 Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids WO2004048409A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003283947A AU2003283947A1 (en) 2002-11-22 2003-11-21 Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200279A SI21373A (en) 2002-11-22 2002-11-22 Method of modulating biological activity of proteins
SIP-200200279 2002-11-22

Publications (2)

Publication Number Publication Date
WO2004048409A2 WO2004048409A2 (en) 2004-06-10
WO2004048409A3 true WO2004048409A3 (en) 2004-09-16

Family

ID=32391126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SI2003/000041 WO2004048409A2 (en) 2002-11-22 2003-11-21 Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids

Country Status (3)

Country Link
AU (1) AU2003283947A1 (en)
SI (1) SI21373A (en)
WO (1) WO2004048409A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108264568B (en) * 2016-12-30 2021-11-16 博晟生医股份有限公司 Recombinant polypeptides, nucleic acid molecules, compositions thereof, and methods of making and using the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1598075A1 (en) * 2004-05-21 2005-11-23 LEK Pharmaceuticals d.d. Process for the isolation and / or purification of proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
WO1997006251A1 (en) * 1995-08-04 1997-02-20 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov, D.D. MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-α RECEPTORS p55 and p75 AS WELL AS AGAINST TNF-α AND ITS ANALOGUES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
WO1997006251A1 (en) * 1995-08-04 1997-02-20 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov, D.D. MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-α RECEPTORS p55 and p75 AS WELL AS AGAINST TNF-α AND ITS ANALOGUES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MENART VIKTOR ET AL: "Increased in vitro cytotoxicity of TNF-alpha analog LK-805 is based on the interaction with cell surface heparan sulfate proteoglycan.", CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS, 2002, Conference on Cell Signaling, Transcription and Translation as Therapeutic Targets;Luxembourg, Luxembourg; January 30-February 02, 2002, New York Academy of Sciences, 2 East 63rd Street, New York, NY,, pages 194 - 206, XP009031717 *
NOVAKOVIC S ET AL: "New TNF-alpha analogues: A powerful but less toxic biological tool against tumours", CYTOKINE, vol. 9, no. 8, 1997, pages 597 - 604, XP002282876, ISSN: 1043-4666 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108264568B (en) * 2016-12-30 2021-11-16 博晟生医股份有限公司 Recombinant polypeptides, nucleic acid molecules, compositions thereof, and methods of making and using the same

Also Published As

Publication number Publication date
AU2003283947A8 (en) 2004-06-18
AU2003283947A1 (en) 2004-06-18
WO2004048409A2 (en) 2004-06-10
SI21373A (en) 2004-06-30

Similar Documents

Publication Publication Date Title
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
BRPI0606612A2 (en) recombinant expression of proteins in a two-chain disulfide linked form
WO2005019251A3 (en) Novel fungal proteins and nucleic acids encoding same
WO2007002373A3 (en) Use of mutant herpes simplex virus-2 for cancer therapy
WO2005121332A3 (en) Truncated st6galnaci polypeptides and nucleic acids
NZ595500A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
WO2002016418A3 (en) An iap binding peptide or polypeptide and methods of using the same
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
WO2006067163A3 (en) Blood pressure lowering oligopeptides in a single enzymatic step
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
EP2343311A3 (en) Peptide inhibitors of HK2 and their use
WO2004048409A3 (en) Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids
WO2006083516A3 (en) Modified cyanovirin-n polypeptide
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
WO2004108761A3 (en) Canine ghrh gene, polypeptides and methods of use
WO2003059943A3 (en) Conformation-specific, protein kinase binding peptides and related methods and products
WO2003057708A3 (en) Fusion proteins
WO2001009352A3 (en) Use of aspergillus sojae as host for recombinant protein production
WO2003059281A3 (en) Novel variants of rankl protein
AU2003264535A1 (en) Tumor antigen protein and utilization thereof
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
WO2005035564A3 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2003073980A3 (en) Recombinant protein c variants
WO2004053052A3 (en) HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (hEOPA)
WO2005116189A3 (en) Compositions and use of inflammation-20 (inf-20) gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP